Compare EVMN & GGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVMN | GGN |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United States | United States |
| Employees | 48 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.5M | 877.0M |
| IPO Year | N/A | N/A |
| Metric | EVMN | GGN |
|---|---|---|
| Price | $22.72 | $5.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $43.88 | N/A |
| AVG Volume (30 Days) | 381.8K | ★ 470.7K |
| Earning Date | 06-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.26% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.89 | $4.31 |
| 52 Week High | $33.20 | $5.88 |
| Indicator | EVMN | GGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.84 | 37.64 |
| Support Level | $21.32 | $5.09 |
| Resistance Level | $23.08 | $5.32 |
| Average True Range (ATR) | 1.25 | 0.07 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 51.43 | 21.25 |
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
GAMCO Global Gold Natural Resources & Income Trust is a non-diversified closed-end management investment company. Its primary investment objective is to provide a high current income and capital appreciation as its secondary objective. To achieve its objective, the fund may invest majority of its assets in equity securities of companies principally engaged in the gold and natural resources industries. It also intends to earn income through an option planning of writing (selling) covered call options on equity securities in its portfolio.